Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SGLT2i: beyond the glucose-lowering effect
Lihua Ni, Yuan Cheng, Guopeng Chen, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 176

Showing 1-25 of 176 citing articles:

Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction
Pasquale Mone, Angela Lombardi, Jessica Gambardella, et al.
Diabetes Care (2022) Vol. 45, Iss. 5, pp. 1247-1251
Open Access | Times Cited: 109
Cognitive impairment and type 2 diabetes mellitus: Focus of SGLT2 inhibitors treatment
Maria Rosaria Rizzo, Irene Di Meo, Rita Polito, et al.
Pharmacological Research (2022) Vol. 176, pp. 106062-106062
Open Access | Times Cited: 107
Empagliflozin attenuates the renal tubular ferroptosis in diabetic kidney disease through AMPK/NRF2 pathway
QianYu Lu, LiJiao Yang, Jing‐Jie Xiao, et al.
Free Radical Biology and Medicine (2022) Vol. 195, pp. 89-102
Closed Access | Times Cited: 104
Associations of semaglutide with first‐time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real‐world data in the US
William Yang Wang, QuangQiu Wang, Xin Qi, et al.
Alzheimer s & Dementia (2024)
Open Access | Times Cited: 19
Comparison of Effectiveness Among Different Sodium‐Glucose Cotransoporter‐2 Inhibitors According to Underlying Conditions: A Network Meta‐Analysis of Randomized Controlled Trials
Ryoma Kani, Atsuyuki Watanabe, Yoshihisa Miyamoto, et al.
Journal of the American Heart Association (2024) Vol. 13, Iss. 3
Open Access | Times Cited: 16
Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics
Zhenghong Liu, Xiaoxuan Ma, Iqra Ilyas, et al.
Theranostics (2021) Vol. 11, Iss. 9, pp. 4502-4515
Open Access | Times Cited: 99
Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment
Nunzia D’Onofrio, Celestino Sardu, Maria Consiglia Trotta, et al.
Molecular Metabolism (2021) Vol. 54, pp. 101337-101337
Open Access | Times Cited: 81
Sodium‐glucose co‐transporter‐2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials
Victor Okunrintemi, Basem M. Mishriky, J.R. Powell, et al.
Diabetes Obesity and Metabolism (2020) Vol. 23, Iss. 1, pp. 276-280
Closed Access | Times Cited: 76
Network Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury
Zhao Min, Shusen Sun, Zhenguang Huang, et al.
Clinical Journal of the American Society of Nephrology (2020) Vol. 16, Iss. 1, pp. 70-78
Open Access | Times Cited: 72
Empagliflozin suppresses mitochondrial reactive oxygen species generation and mitigates the inducibility of atrial fibrillation in diabetic rats
Takuya Koizumi, Masaya Watanabe, Takashi Yokota, et al.
Frontiers in Cardiovascular Medicine (2023) Vol. 10
Open Access | Times Cited: 33
Sodium-glucose cotransporter-2 inhibitors (SGLT2) in frail or older people with type 2 diabetes and heart failure: a systematic review and meta-analysis
Rami Aldafas, Thomas Crabtree, Mohammed Alkharaiji, et al.
Age and Ageing (2024) Vol. 53, Iss. 1
Open Access | Times Cited: 15
Comparative effectiveness of second line oral antidiabetic treatments among people with type 2 diabetes mellitus: emulation of a target trial using routinely collected health data
Patrick Bidulka, David G. Lugo‐Palacios, Orlagh Carroll, et al.
BMJ (2024), pp. e077097-e077097
Open Access | Times Cited: 13
Differing Efficacy of Dapagliflozin Versus Empagliflozin on the Risk of Incident Atrial Fibrillation in Patients With Type 2 Diabetes: A Real‐World Observation Using a Nationwide, Population‐Based Cohort
Jae-Hyun Lim, Soongu Kwak, You‐Jung Choi, et al.
Journal of the American Heart Association (2024) Vol. 13, Iss. 3
Open Access | Times Cited: 11
Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes
P. Natale, David J. Tunnicliffe, Tadashi Toyama, et al.
Cochrane library (2024) Vol. 2024, Iss. 5
Closed Access | Times Cited: 10
Role and molecular mechanisms of SGLT2 inhibitors in pathological cardiac remodeling (Review)
B K Chen, Jing Guo, Ye Hongmei, et al.
Molecular Medicine Reports (2024) Vol. 29, Iss. 5
Open Access | Times Cited: 9
SGLT2 inhibitor promotes mitochondrial dysfunction and ER-phagy in colorectal cancer cells
Camilla Anastasio, Isabella Donisi, Vitale Del Vecchio, et al.
Cellular & Molecular Biology Letters (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 9
Type 2 Diabetes Mellitus: A Comprehensive Review of Pathophysiology, Comorbidities, and Emerging Therapies
Aditi Singh, Sucharita Shadangi, Pulkit Kr. Gupta, et al.
Comprehensive physiology (2025) Vol. 15, Iss. 1
Closed Access | Times Cited: 1
The effects of sodium-glucose transporter 2 inhibition on cardiac surgery-associated acute kidney injury: An open-label randomized pilot study
L. Snel, Maartina J.P. Oosterom-Eijmael, Elena Rampanelli, et al.
Journal of Clinical Anesthesia (2025) Vol. 103, pp. 111811-111811
Open Access | Times Cited: 1
Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection
Yi‐Chou Hou, Cai‐Mei Zheng, Tzung‐Hai Yen, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 21, pp. 7833-7833
Open Access | Times Cited: 70
Association of SGLT2 Inhibitors With Risk of Atrial Fibrillation and Stroke in Patients With and Without Type 2 Diabetes: A Systemic Review and Meta-Analysis of Randomized Controlled Trials
Rujie Zheng, Yue Wang, Junnan Tang, et al.
Journal of Cardiovascular Pharmacology (2021) Vol. 79, Iss. 2, pp. e145-e152
Open Access | Times Cited: 49
Dapagliflozin ameliorates sepsis-induced heart injury by inhibiting cardiomyocyte apoptosis and electrical remodeling through the PI3K/Akt pathway
Xueyu Han, Xin Liu, Xin Zhao, et al.
European Journal of Pharmacology (2023) Vol. 955, pp. 175930-175930
Open Access | Times Cited: 18
Empagliflozin improves renal ischemia–reperfusion injury by reducing inflammation and enhancing mitochondrial fusion through AMPK–OPA1 pathway promotion
Wenbo Yang, Xiaoli Li, Liujie He, et al.
Cellular & Molecular Biology Letters (2023) Vol. 28, Iss. 1
Open Access | Times Cited: 17
Atrial Cardiomyopathy in Valvular Heart Disease: From Molecular Biology to Clinical Perspectives
Andrea Molnár, Attila Sánta, Dorottya Pásztor, et al.
Cells (2023) Vol. 12, Iss. 13, pp. 1796-1796
Open Access | Times Cited: 17
SGLT2 and DPP4 inhibitors improve Alzheimer’s disease–like pathology and cognitive function through distinct mechanisms in a T2D–AD mouse model
Adelene Y. L. Sim, Da Hyun Choi, Jong Youl Kim, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 168, pp. 115755-115755
Open Access | Times Cited: 17
Exploring antidiabetic drug targets as potential disease-modifying agents in osteoarthritis
Kai Fu, Shucheng Si, Xinzhong Jin, et al.
EBioMedicine (2024) Vol. 107, pp. 105285-105285
Closed Access | Times Cited: 6
Page 1 - Next Page

Scroll to top